A Chemical Proteomics Approach for the Identification of Accessible Antigens Expressed in Human Kidney Cancer (Q57912088)

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Genes expressed in human tumor endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

In silico cloning of novel endothelial-specific genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Organ targeting in vivo using phage display peptide libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Quantitative analysis of complex protein mixtures using isotope-coded affinity tags

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Assignment of protein function in the postgenomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Design, construction, and characterization of a large synthetic human antibody phage display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Making antibodies by phage display technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

ED-B fibronectin as a target for antibody-based cancer treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

The human plasma proteome: history, character, and diagnostic prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

The role of carbonic anhydrase IX overexpression in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-1 (E-NPP1/PC-1) and -3 (E-NPP3/CD203c/PD-Ibeta/B10/gp130(RB13-6)) in inflammatory and neoplastic bile duct diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

A human protein atlas for normal and cancer tissues based on antibody proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Expression of Periostin, homologous with an insect cell adhesion molecule, as a prognostic marker in non-small cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Periostin induction in tumor cell line explants and inhibition of in vitro cell growth by anti-periostin antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Versican expression in pharyngeal squamous cell carcinoma: an immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Versican in epithelial ovarian cancer: Relation to hyaluronan, clinicopathologic factors and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Drug-conjugated monoclonal antibodies for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Fibronectin as target for tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200

Expression profiling by high-throughput immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M600164-MCP200